Why This Data Is Making Puma Biotechnology, Inc Shares Collapse
By Todd Campbell | More Articles
May 14, 2015 | Comments (0)
What: Shares in Puma Biotechnology (NYSE: PBYI ) collapsed by more than 15% earlier today after abstracts to be presented at the upcoming American Society of Clinical Oncology meeting were released.
So What: The abstracts include data on Puma Biotechnology's neratinib, or PB272, a cancer-fighting drug that is the company's lead product candidate.
How much does it cost to receive breaking news feed?
Sarepta Therapeutics Positive Meeting with FDA
The Fly 5/15/15
Top Stock Mutual Fund New Buys: CyberArk Software
BY JULIE MAK, INVESTOR'S BUSINESS DAILY
05/05/2015 06:28 PM ET
a good buy here .